The effect of etoricoxib on the pharmacokinetics of oral contraceptives in healthy participants

Jules Schwartz, Thomas Hunt, William Smith, Peggy Wong, Patrick Larson, Tami Crumley, Anish Mehta, Keith Gottesdiener, Nancy Agrawal

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The pharmacokinetics of oral contraceptive (OC) components, ethinyl estradiol (EE) and norethindrone (NET), were evaluated after coadministration with etoricoxib in 3 double-blind, randomized, 2-period crossover studies of healthy women. There were 16, 39, and 24 participants enrolled in studies 1 (part I, part II), and 2, respectively. Each participant received triphasic OC (EE 35 μg/NET 0.5 mg × 7 days, 0.75 mg × 7 days, 1.0 mg × 7 days) throughout each 28-day period. OC was coadministered with 21 days of etoricoxib daily followed by placebo for 7 days; the alternate period followed the reverse regimen (placebo to etoricoxib). Study 1 (part I) examined concurrent (morning) administration of OC/etoricoxib 120 mg, study 1 (part II) examined staggered (morning/night) administration of OC/etoricoxib 120 mg, and study 2 examined concurrent (morning) administration of OC/etoricoxib 60 mg. Coadministration of OC and etoricoxib 120 mg once daily was associated with a ∼50% to 60% increase in EE concentrations, whereas etoricoxib 60 mg once daily was associated with a ∼37% increase in EE concentrations. Coadministration of OC and etoricoxib was generally well tolerated. A clinically important change in NET AUC 0-24 h was not observed. Adverse events included dyspepsia, diarrhea, headache, nausea, fatigue, loss of appetite, and taste disturbance.

Original languageEnglish (US)
Pages (from-to)807-815
Number of pages9
JournalJournal of clinical pharmacology
Volume49
Issue number7
DOIs
StatePublished - Jul 1 2009

Fingerprint

etoricoxib
Oral Contraceptives
Healthy Volunteers
Pharmacokinetics
Ethinyl Estradiol
Norethindrone
Placebos
Dyspepsia

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

The effect of etoricoxib on the pharmacokinetics of oral contraceptives in healthy participants. / Schwartz, Jules; Hunt, Thomas; Smith, William; Wong, Peggy; Larson, Patrick; Crumley, Tami; Mehta, Anish; Gottesdiener, Keith; Agrawal, Nancy.

In: Journal of clinical pharmacology, Vol. 49, No. 7, 01.07.2009, p. 807-815.

Research output: Contribution to journalArticle

Schwartz, J, Hunt, T, Smith, W, Wong, P, Larson, P, Crumley, T, Mehta, A, Gottesdiener, K & Agrawal, N 2009, 'The effect of etoricoxib on the pharmacokinetics of oral contraceptives in healthy participants', Journal of clinical pharmacology, vol. 49, no. 7, pp. 807-815. https://doi.org/10.1177/0091270009337131
Schwartz, Jules ; Hunt, Thomas ; Smith, William ; Wong, Peggy ; Larson, Patrick ; Crumley, Tami ; Mehta, Anish ; Gottesdiener, Keith ; Agrawal, Nancy. / The effect of etoricoxib on the pharmacokinetics of oral contraceptives in healthy participants. In: Journal of clinical pharmacology. 2009 ; Vol. 49, No. 7. pp. 807-815.
@article{c29c7fcb1c774ae8ae64f3292df86d61,
title = "The effect of etoricoxib on the pharmacokinetics of oral contraceptives in healthy participants",
abstract = "The pharmacokinetics of oral contraceptive (OC) components, ethinyl estradiol (EE) and norethindrone (NET), were evaluated after coadministration with etoricoxib in 3 double-blind, randomized, 2-period crossover studies of healthy women. There were 16, 39, and 24 participants enrolled in studies 1 (part I, part II), and 2, respectively. Each participant received triphasic OC (EE 35 μg/NET 0.5 mg × 7 days, 0.75 mg × 7 days, 1.0 mg × 7 days) throughout each 28-day period. OC was coadministered with 21 days of etoricoxib daily followed by placebo for 7 days; the alternate period followed the reverse regimen (placebo to etoricoxib). Study 1 (part I) examined concurrent (morning) administration of OC/etoricoxib 120 mg, study 1 (part II) examined staggered (morning/night) administration of OC/etoricoxib 120 mg, and study 2 examined concurrent (morning) administration of OC/etoricoxib 60 mg. Coadministration of OC and etoricoxib 120 mg once daily was associated with a ∼50{\%} to 60{\%} increase in EE concentrations, whereas etoricoxib 60 mg once daily was associated with a ∼37{\%} increase in EE concentrations. Coadministration of OC and etoricoxib was generally well tolerated. A clinically important change in NET AUC 0-24 h was not observed. Adverse events included dyspepsia, diarrhea, headache, nausea, fatigue, loss of appetite, and taste disturbance.",
author = "Jules Schwartz and Thomas Hunt and William Smith and Peggy Wong and Patrick Larson and Tami Crumley and Anish Mehta and Keith Gottesdiener and Nancy Agrawal",
year = "2009",
month = "7",
day = "1",
doi = "10.1177/0091270009337131",
language = "English (US)",
volume = "49",
pages = "807--815",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "7",

}

TY - JOUR

T1 - The effect of etoricoxib on the pharmacokinetics of oral contraceptives in healthy participants

AU - Schwartz, Jules

AU - Hunt, Thomas

AU - Smith, William

AU - Wong, Peggy

AU - Larson, Patrick

AU - Crumley, Tami

AU - Mehta, Anish

AU - Gottesdiener, Keith

AU - Agrawal, Nancy

PY - 2009/7/1

Y1 - 2009/7/1

N2 - The pharmacokinetics of oral contraceptive (OC) components, ethinyl estradiol (EE) and norethindrone (NET), were evaluated after coadministration with etoricoxib in 3 double-blind, randomized, 2-period crossover studies of healthy women. There were 16, 39, and 24 participants enrolled in studies 1 (part I, part II), and 2, respectively. Each participant received triphasic OC (EE 35 μg/NET 0.5 mg × 7 days, 0.75 mg × 7 days, 1.0 mg × 7 days) throughout each 28-day period. OC was coadministered with 21 days of etoricoxib daily followed by placebo for 7 days; the alternate period followed the reverse regimen (placebo to etoricoxib). Study 1 (part I) examined concurrent (morning) administration of OC/etoricoxib 120 mg, study 1 (part II) examined staggered (morning/night) administration of OC/etoricoxib 120 mg, and study 2 examined concurrent (morning) administration of OC/etoricoxib 60 mg. Coadministration of OC and etoricoxib 120 mg once daily was associated with a ∼50% to 60% increase in EE concentrations, whereas etoricoxib 60 mg once daily was associated with a ∼37% increase in EE concentrations. Coadministration of OC and etoricoxib was generally well tolerated. A clinically important change in NET AUC 0-24 h was not observed. Adverse events included dyspepsia, diarrhea, headache, nausea, fatigue, loss of appetite, and taste disturbance.

AB - The pharmacokinetics of oral contraceptive (OC) components, ethinyl estradiol (EE) and norethindrone (NET), were evaluated after coadministration with etoricoxib in 3 double-blind, randomized, 2-period crossover studies of healthy women. There were 16, 39, and 24 participants enrolled in studies 1 (part I, part II), and 2, respectively. Each participant received triphasic OC (EE 35 μg/NET 0.5 mg × 7 days, 0.75 mg × 7 days, 1.0 mg × 7 days) throughout each 28-day period. OC was coadministered with 21 days of etoricoxib daily followed by placebo for 7 days; the alternate period followed the reverse regimen (placebo to etoricoxib). Study 1 (part I) examined concurrent (morning) administration of OC/etoricoxib 120 mg, study 1 (part II) examined staggered (morning/night) administration of OC/etoricoxib 120 mg, and study 2 examined concurrent (morning) administration of OC/etoricoxib 60 mg. Coadministration of OC and etoricoxib 120 mg once daily was associated with a ∼50% to 60% increase in EE concentrations, whereas etoricoxib 60 mg once daily was associated with a ∼37% increase in EE concentrations. Coadministration of OC and etoricoxib was generally well tolerated. A clinically important change in NET AUC 0-24 h was not observed. Adverse events included dyspepsia, diarrhea, headache, nausea, fatigue, loss of appetite, and taste disturbance.

UR - http://www.scopus.com/inward/record.url?scp=67650435076&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650435076&partnerID=8YFLogxK

U2 - 10.1177/0091270009337131

DO - 10.1177/0091270009337131

M3 - Article

C2 - 19443681

AN - SCOPUS:67650435076

VL - 49

SP - 807

EP - 815

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 7

ER -